MAGEA3 and neoplasm: MG1 encoding the cancer/testis antigen MAGE-A3 has been used as part of an OV/tumour vaccine approach and MG1 encoding microRNA molecules have been used to skew tumour-infiltrating macrophages from an M2-like (pro-tumour) immunosuppressive phenotype to an M1-like pro-inflammatory/anti-tumour phenotype in ovarian cancer models [65].